Michel Vounatsos, Biogen CEO (Dina Rudick/The Boston Globe via Getty Images)
Aduhelm struggles barely affected CEO Michel Vounatsos' $17.7M pay
Last year was a difficult one for Biogen, as it got off to a rough start with its controversial Alzheimer’s drug Aduhelm — but that barely …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
